Details
Stereochemistry | RACEMIC |
Molecular Formula | C15H23NO |
Molecular Weight | 233.3492 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCC1(CCCCN(C)C1)C2=CC(O)=CC=C2
InChI
InChIKey=JLICHNCFTLFZJN-UHFFFAOYSA-N
InChI=1S/C15H23NO/c1-3-15(9-4-5-10-16(2)12-15)13-7-6-8-14(17)11-13/h6-8,11,17H,3-5,9-10,12H2,1-2H3
Molecular Formula | C15H23NO |
Molecular Weight | 233.3492 |
Charge | 0 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Optical Activity | ( + / - ) |
DescriptionCurator's Comment: description was created based on several sources, including:
http://www.shijiebiaopin.net/upload/product/201222217302623.PDF | https://www.drugs.com/uk/meptid-tablets-200mg-leaflet.html
Curator's Comment: description was created based on several sources, including:
http://www.shijiebiaopin.net/upload/product/201222217302623.PDF | https://www.drugs.com/uk/meptid-tablets-200mg-leaflet.html
Meptazinol is a unique opioid analgesic. Binding studies suggest a relative selectivity for mu-1 opioid receptor sites. Meptid is indicated for the treatment of moderate to severe pain, including post-operative pain, obstetric pain and the pain of renal colic. The most commonly reported adverse reactions after treatment with meptazinol are nausea, vomiting, dizziness, diarrhoea and increased sweating, constipation, abdominal pain, rash, vertigo, headache, drowsiness, somnolence and dyspepsia.
CNS Activity
Originator
Sources: https://encrypted.google.com/patents/DE1941534A1
Curator's Comment: # Wyeth John & Brother Ltd.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: P81908 Gene ID: NA Gene Symbol: BCHE Target Organism: Equus caballus (Horse) Sources: https://www.ncbi.nlm.nih.gov/pubmed/3607358 |
3.6 µM [IC50] | ||
Target ID: CHEMBL3198 Sources: https://www.ncbi.nlm.nih.gov/pubmed/3607358 |
0.4 µM [IC50] | ||
8.0 nM [Kd] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Meptid Approved UseThe drug is indicated for the treatment of moderate to severe pain, including post-operative pain, obstetric pain and the pain of renal colic. |
|||
Primary | Meptid Approved UseThe drug is indicated for the treatment of moderate to severe pain, including post-operative pain, obstetric pain and the pain of renal colic. |
|||
Primary | Meptid Approved UseThe drug is indicated for the treatment of moderate to severe pain, including post-operative pain, obstetric pain and the pain of renal colic. |
PubMed
Title | Date | PubMed |
---|---|---|
Intramuscular on demand analgesia: double blind controlled trial of pethidine, buprenorphine, morphine, and meptazinol. | 1983 Feb 26 |
|
Comparison of the cardiovascular effects of meptazinol and naloxone following haemorrhagic shock in rats and cats. | 1985 Sep |
|
Lack of sensitization during place conditioning in rats is consistent with the low abuse potential of tramadol. | 2002 Aug 23 |
|
Enhancement of systemic and CNS delivery of meptazinol hydrochloride by intranasal administration to rats. | 2005 Aug |
|
A novel method to calculate the extent and amount of drug transported into CSF after intranasal administration. | 2005 Jan 31 |
|
Structural comparisons of meptazinol with opioid analgesics. | 2005 Mar |
|
Synthesis and relative bioavailability of meptazinol benzoyl esters as prodrugs. | 2005 May 16 |
|
Pharmacokinetic behavior in plasma, cerebrospinal fluid and cerebral cortex after intranasal administration of hydrochloride meptazinol. | 2005 Sep 30 |
|
Investigation of the binding mode of (-)-meptazinol and bis-meptazinol derivatives on acetylcholinesterase using a molecular docking method. | 2006 Mar |
|
Conformational re-analysis of (+)-meptazinol: an opioid with mixed analgesic pharmacophores. | 2006 Sep |
|
WITHDRAWN: Types of intra-muscular opioids for maternal pain relief in labour. | 2007 Jul 18 |
|
Bis-(-)-nor-meptazinols as novel nanomolar cholinesterase inhibitors with high inhibitory potency on amyloid-beta aggregation. | 2008 Apr 10 |
|
(3S,4S)-3-Ethyl-4-hydr-oxy-3-(3-methoxy-phen-yl)-1-methyl-azepan-1-ium d-tartrate dihydrate. | 2008 Apr 2 |
|
Prescribing intramuscular opioids for labour analgesia in consultant-led maternity units: a survey of UK practice. | 2008 Jan |
|
1-Methyl-3-(3-oxocyclo-hex-1-en-yl)azepan-2-one. | 2008 Sep 13 |
|
The crystal structure of a complex of acetylcholinesterase with a bis-(-)-nor-meptazinol derivative reveals disruption of the catalytic triad. | 2009 Apr 23 |
|
Liquid chromatography/positive ion electrospray tandem mass spectrometry method for the quantification of hydrochloride meptazinol in human plasma: application to a pharmacokinetic study. | 2009 Nov 15 |
|
In situ and in vivo study of nasal absorption of paeonol in rats. | 2010 |
|
[Patient-controlled intravenous analgesia with remifentanil as an alternative to epidural analgesia during labor: case series and discussion of medicolegal aspects]. | 2010 Aug |
Patents
Sample Use Guides
Oral: One tablet (200 mg), with a glass of water, every four hours.
Intramuscular: 75-100mg. The injection may be repeated 2-4 hourly as required. For obstetric pain a dose of 100-150mg should be used according to weight. This dose should approximate 2mg/kg.
Intravenous: 50-100mg by slow intravenous injection. The injection may be repeated 2-4 hourly as required. If vomiting occurs, a suitable antiemetic should be given.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/6141283
Approximately 20 to 40% of 3H-opiate binding is inhibited by meptazinol at concentrations less than 5 nM, whereas the inhibition for D-[3H]Ala2-D-Leu5-enkaphalin usually ranges from 15 to 20%.
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 16:05:06 UTC 2023
by
admin
on
Sat Dec 16 16:05:06 UTC 2023
|
Record UNII |
18Y7S5JKZD
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QN02AX05
Created by
admin on Sat Dec 16 16:05:07 UTC 2023 , Edited by admin on Sat Dec 16 16:05:07 UTC 2023
|
||
|
WHO-ATC |
N02AX05
Created by
admin on Sat Dec 16 16:05:07 UTC 2023 , Edited by admin on Sat Dec 16 16:05:07 UTC 2023
|
||
|
LIVERTOX |
602
Created by
admin on Sat Dec 16 16:05:07 UTC 2023 , Edited by admin on Sat Dec 16 16:05:07 UTC 2023
|
||
|
NCI_THESAURUS |
C67413
Created by
admin on Sat Dec 16 16:05:07 UTC 2023 , Edited by admin on Sat Dec 16 16:05:07 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
54340-58-8
Created by
admin on Sat Dec 16 16:05:07 UTC 2023 , Edited by admin on Sat Dec 16 16:05:07 UTC 2023
|
PRIMARY | |||
|
MEPTAZINOL
Created by
admin on Sat Dec 16 16:05:07 UTC 2023 , Edited by admin on Sat Dec 16 16:05:07 UTC 2023
|
PRIMARY | |||
|
1706
Created by
admin on Sat Dec 16 16:05:07 UTC 2023 , Edited by admin on Sat Dec 16 16:05:07 UTC 2023
|
PRIMARY | |||
|
SUB08761MIG
Created by
admin on Sat Dec 16 16:05:07 UTC 2023 , Edited by admin on Sat Dec 16 16:05:07 UTC 2023
|
PRIMARY | |||
|
DTXSID6048543
Created by
admin on Sat Dec 16 16:05:07 UTC 2023 , Edited by admin on Sat Dec 16 16:05:07 UTC 2023
|
PRIMARY | |||
|
DB13478
Created by
admin on Sat Dec 16 16:05:07 UTC 2023 , Edited by admin on Sat Dec 16 16:05:07 UTC 2023
|
PRIMARY | |||
|
m7200
Created by
admin on Sat Dec 16 16:05:07 UTC 2023 , Edited by admin on Sat Dec 16 16:05:07 UTC 2023
|
PRIMARY | Merck Index | ||
|
100000081482
Created by
admin on Sat Dec 16 16:05:07 UTC 2023 , Edited by admin on Sat Dec 16 16:05:07 UTC 2023
|
PRIMARY | |||
|
D008621
Created by
admin on Sat Dec 16 16:05:07 UTC 2023 , Edited by admin on Sat Dec 16 16:05:07 UTC 2023
|
PRIMARY | |||
|
CHEMBL314437
Created by
admin on Sat Dec 16 16:05:07 UTC 2023 , Edited by admin on Sat Dec 16 16:05:07 UTC 2023
|
PRIMARY | |||
|
3605
Created by
admin on Sat Dec 16 16:05:07 UTC 2023 , Edited by admin on Sat Dec 16 16:05:07 UTC 2023
|
PRIMARY | |||
|
C87360
Created by
admin on Sat Dec 16 16:05:07 UTC 2023 , Edited by admin on Sat Dec 16 16:05:07 UTC 2023
|
PRIMARY | |||
|
259-109-9
Created by
admin on Sat Dec 16 16:05:07 UTC 2023 , Edited by admin on Sat Dec 16 16:05:07 UTC 2023
|
PRIMARY | |||
|
6761
Created by
admin on Sat Dec 16 16:05:07 UTC 2023 , Edited by admin on Sat Dec 16 16:05:07 UTC 2023
|
PRIMARY | RxNorm | ||
|
18Y7S5JKZD
Created by
admin on Sat Dec 16 16:05:07 UTC 2023 , Edited by admin on Sat Dec 16 16:05:07 UTC 2023
|
PRIMARY | |||
|
41049
Created by
admin on Sat Dec 16 16:05:07 UTC 2023 , Edited by admin on Sat Dec 16 16:05:07 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ENANTIOMER -> RACEMATE | |||
|
SALT/SOLVATE -> PARENT | |||
|
ENANTIOMER -> RACEMATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |